Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etoposide + doxorubicin + cisplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
EDP is a combination chemotherapy regimen comprising etoposide, doxorubicin, and cisplatin. It is primarily recognized as the standard-of-care chemotherapy backbone for advanced or metastatic adrenocortical carcinoma (ACC), typically administered alongside mitotane (the EDP-M regimen). The regimen's efficacy stems from the complementary mechanisms of its components: etoposide and doxorubicin inhibit topoisomerase II, preventing DNA ligation and inducing double-strand breaks, while cisplatin creates covalent DNA cross-links that impede replication and transcription. Doxorubicin further contributes via DNA intercalation. This multi-targeted approach effectively induces apoptosis in high-grade malignancies but is associated with significant toxicities, including myelosuppression and gastrointestinal distress.
- Other names
- EDP regimenEtoposide-Doxorubicin-Cisplatin依托泊苷 + 多柔比星 + 顺铂
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on etoposide + doxorubicin + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etoposide + doxorubicin + cisplatin.